Serotonin Syndrome vs NMS: Key Differences (50-60 chars)

Four syndromes require differential diagnosis: Serotonin Syndrome (rapid onset, dilated pupils, hyperreflexia, hyperexcitation), Neuroleptic Malignant Syndrome (slower onset, normal pupils, rigidity, stupor/coma), Anticholinergic Toxicity (dry hyperthermia, dilated pupils, decreased motility), and Malignant Hyperthermia (most rapid, triggered by anesthetics). Key differentiating features include onset speed, pupil size, sweating status, muscle tone, reflexes, and patient consciousness. All except Anticholinergic Toxicity share hypertension, tachycardia, tachypnea, and hyperthermia.

Malignant hyperthermia presents with hypercarbia, tachycardia, and hyperthermia. Key differentials include inadequate anesthesia (respiratory acidosis without temperature change), rebreathing (low fresh gas flow), increased CO2 absorption (pneumoperitoneum/surgical emphysema), fever (causes tachycardia but lowers PaCO2), sepsis, anaphylaxis (hypotension), anesthesia-induced abductinolysis, thyroid toxicity, transfusion reactions, drug abuse (cocaine/ecstasy/MDMA/methamphetamine causing serotonin syndrome), neuroleptic malignant syndrome, hypoxic brain injury, and benzodiazepine withdrawal. Each differential has distinct features that help distinguish from MH.

Three hyperthermic syndromes can occur after anesthesia: (1) Malignant hyperthermia - triggered by succinylcholine/halothane, treated with dantrolene, (2) Neuroleptic malignant syndrome - caused by antipsychotics, treated with bromocriptine/dantrolene, (3) Serotonin syndrome - caused by serotonergic drugs, treated with cyproheptadine. Succinylcholine has important side effects: prolonged paralysis in pseudocholinesterase deficiency, malignant hyperthermia in susceptible patients, and hyperkalemia due to potassium efflux. Recognizing malignant hyperthermia requires identifying the classic triad: hyperthermia, muscle rigidity, and elevated creatine kinase. Accurate diagnosis based on medication history and clinical features is essential for appropriate treatment.

Malignant hyperthermia requires differentiation from multiple conditions including inadequate anesthesia, insufficient ventilation, sepsis, thyroid storm, pheochromocytoma, neuromuscular disorders, serotonin syndrome, and neuroleptic malignant syndrome. Key distinguishing factors include trigger agents and clinical presentations. MH triggers are inhalational anesthetics or succinylcholine with rapid onset (minutes to 2 hours), while NMS triggers are antipsychotics/anti-parkinsonian drugs with delayed onset (days to weeks), and serotonin syndrome triggers are serotonergic agents with intermediate onset (hours). MH presents with muscle rigidity and metabolic crisis, NMS with catatonia and autonomic instability, and serotonin syndrome with confusion, myoclonus, and hyperreflexia. Other hyperthermia causes include hypothalamic lesions, exercise, salicylate/cocaine poisoning, hyperthyroidism, pheochromocytoma, status epilepticus, and tetanus.

When three or four signs of malignant hyperthermia are present with abnormal anion gap and potassium levels, immediately call for help, inform the surgeon, and remove triggering agents. Administer dantrolene sodium at 2-2.5 mg/kg IV. Intubate and hyperventilate with 100% oxygen. Initiate active cooling using cooling blankets and irrigate with cold fluids. Promote diuresis targeting 1-2 ml/kg/hour urine output with IV fluids at 10 ml/kg over 15 minutes. Treat complications including acidosis, hyperkalemia, and dysrhythmias while avoiding calcium channel blockers which worsen hyperkalemia. DIC is treated with fresh frozen plasma, platelets, and cryoprecipitate; compartment syndrome may require surgical fasciotomy. Post-crisis management includes monitoring laboratory values (arterial blood gases, lactates, electrolytes, serum myoglobin, urine myoglobin, creatine kinase, coagulation profile) and reporting to the malignant hyperthermia registry. Refer patients to diagnostic centers and issue medical alert bracelets. First-degree relatives should undergo screening. Differential diagnoses include inadequate anesthesia depth, anesthesia machine malfunction, sepsis, thyroid crisis (presenting with psychosis, delirium, slower temperature progression to 104-106°F), and neuroleptic malignant syndrome (onset from days to weeks, catatonic mental status, mild hypothermia <102.5°F, muscle rigidity with hyporeflexia).

Many serotonergic medications have long half-lives requiring washout periods before initiating other medications. MAOIs and other serotonergic agents should not be overlapped without proper washout due to highest risk of serotonin syndrome. Switching from MAOI to SSRI/SNRI requires 14-day washout. Switching from SSRI/SNRI to MAOI depends on half-life and active metabolites. Venlafaxine, clomipramine, and imipramine have active metabolites with longer half-lives (12-70 hours), requiring 2-week washout. Fluoxetine has longest half-life (2 days) with active metabolite norfluoxetine (10 days), requiring 5-6 week washout.

Antidepressants are classified into three main categories: Tricyclic Antidepressants (TCAs), Selective Serotonin Reuptake Inhibitors (SSRIs), and Monoamine Oxidase Inhibitors (MAOIs). When switching from MAOIs to SSRIs, a minimum 10-14 day gap must be maintained between discontinuing one drug and starting the other to prevent serotonin syndrome. Serotonin syndrome is a potentially life-threatening condition caused by excessive serotonin levels, presenting with agitation, confusion, rapid heart rate, and muscle rigidity. The key principle is to never combine serotonergic medications without proper washout periods.

SSRIs should never be mixed with St. John's Wort, and MAOIs should never be combined with other antidepressants including TCAs, SSRIs, or SNRIs. This combination can lead to deadly serotonin syndrome. A two-week washout period is required when switching between these medications. Never start a new antidepressant while still tapering off another; patients must fully complete the washout period before beginning a new medication.

Safe antidepressant switching strategies include: (1) Direct switch: suitable when fast-acting antidepressant used for less than six weeks; (2) Taper and immediate switch: reduce first antidepressant, stop it, then start new medication the next day at smaller dose; (3) Cross-tapering: reduce first medication while starting new one, reducing each by 25% weekly; (4) Avoid tricyclics and MAOIs due to washout period requirements; (5) Be mindful of CYP450 interactions (e.g., fluvoxamine cannot be given with venlafaxine).

Switchrx.com provides evidence-based algorithms for antidepressant switching. Direct switch (stop one, start another immediately) is safe if patient has been on first medication <6 weeks or experienced severe adverse reaction. Taper-first approach is safer for longer-term users. Cross-taper involves simultaneous down-titration of one and up-titration of the other, reducing withdrawal risk but increasing interaction risk. Washout periods are required when switching from MAOIs to SSRIs or vice versa. For example, switching from citalopram to sertraline involves starting sertraline at 25mg while tapering citalopram by 10mg weekly.

This section covers the complete clinical approach to electrocution-induced rhabdomyolysis and AKI. Key topics include: clinical presentation with altered sensorium, muscle pain, and dark urine; cardiopulmonary complications including respiratory and cardiac arrest mechanisms; comprehensive trauma assessment using ATLS; pathophysiology of rhabdomyolysis causing high anion gap metabolic acidosis, hyperkalemia, hyperphosphatemia, hypocalcemia, and hyperuricemia; myoglobin-induced AKI through ferro-ferric conversion causing tubular necrosis; aggressive fluid resuscitation protocols targeting 1-3 mL/kg/hour urine output; volume status assessment using IVC ultrasound and passive leg raising test; and emergency electrolyte management for hyperkalemia exceeding 6.5 mEq/L requiring calcium gluconate, glucose-insulin drip, nebulized albuterol, and potassium binders.

Close monitoring of vital signs, serial CK, and hourly urine output is essential. High-risk patients require critical care with serial examinations for complications including compartment syndrome, hyperkalemia, renal failure, DIC, and cardiac failure. Resolution is assessed by serial CK levels. Urinary alkalinization (target pH 6.5) may be considered for CK >6,000 with acidemia, dehydration, or renal disease, though evidence is limited to animal and retrospective studies. Mannitol benefits include flushing nephrotoxins and free radical scavenging, but risks hypovolemia. Furosemide increases urinary output in oliguric patients despite adequate volume. Renal replacement therapy indications include oliguric renal failure, persistent hyperkalemia despite therapy, other electrolyte abnormalities, persistent metabolic acidosis, and volume overload. Consultations include nephrologists for dialysis needs, neurologists for seizures, orthopedic surgeons for fractures/compartment syndrome, poison control for overdoses, geneticists for metabolic diseases, and rheumatologists for inflammatory myopathies. Free radical scavengers (pentoxifylline, vitamins C/E) lack controlled study evidence. Outpatient management is appropriate for well-hydrated patients with stable vitals, normal renal function, electrolytes, alkaline urine, isolated injury cause, and no inpatient indications. Stop inciting myotoxic agents. Genetic counseling may be indicated for family members with inherited muscle enzyme deficiencies.

Patients with documented histories of autonomic instability under anesthesia recovery may experience specific cardiac arrhythmias that require immediate intervention. The intervention protocol for such presentations includes specific medications and timing. When such protocols are followed, the patient's condition can stabilize. The ability to recognize and respond to these specific presentations represents specialized knowledge that may not be available in standard civilian settings.

Prehospital care emphasizes early aggressive IV fluid resuscitation with normal saline at 1L/hour initially, then alternating with 500mL/hour of normal saline and 5% dextrose. Emergency department management continues IV rehydration for 24-72 hours targeting 3-4mL/kg/hour urine output. While urine alkalinization and forced diuresis lack strong evidence, mannitol and bicarbonate may reduce acute renal dysfunction risk in CK >10,000 IU/L. Electrolyte management addresses hyperkalemia (most severe 12-36 hours post-injury) with insulin/glucose and ion exchange resins, and hyperphosphatemia (>7mg/dL) with phosphate binders. Complications include acute kidney injury from hypovolemia, acidosis, tubular obstruction, and myoglobin nephrotoxicity; compartment syndrome requiring urgent intervention; and peripheral neuropathy causing paresthesias or paralysis. Disposition depends on severity—healthy patients without comorbidities may be discharged after rehydration, while high-risk patients require monitored bed admission for 24-48 hours and nephrology consultation for refractory hyperkalemia or high McMahon risk score.

Severe crush injuries from snares can cause rhabdomyolysis, the rapid breakdown of muscle tissue releasing lethal levels of potassium and myoglobin into the bloodstream. This condition causes kidney failure as the kidneys struggle to filter the released toxins. Treatment requires immediate dialysis and may involve induced comas to allow machines to filter deadly toxins from the blood while the body recovers.